查看購物車
  • Simplified Chinese
  • English
  • Japanese
封面
市場調查報告書
商品編碼
1863422

生物製造領域病毒檢測與定量市場：按產品、技術、應用、最終用戶和樣品類型分類－2025-2032年全球預測

Biomanufacturing Viral Detection & Quantification Market by Product, Technology, Application, End User, Sample Type - Global Forecast 2025-2032
出版日期: | 出版商: 360iResearch | 英文 193 Pages | 商品交期: 最快1-2個工作天內

價格

※ 本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

預計到 2032 年，生物製造領域的病毒檢測和定量市場將成長至 56.3 億美元，複合年成長率為 8.67%。

關鍵市場統計數據
基準年 2024 28.9億美元
預計年份：2025年 31.4億美元
預測年份 2032 56.3億美元
複合年成長率 (%) 8.67%

深入探討先進的病毒檢測和定量技術如何成為現代生物製造品質和營運韌性的基礎

隨著精準檢測技術從實驗室走向受監管的生產環境，支持病毒檢測和定量分析的生物製造環境正在迅速發展。分子診斷技術的進步，結合自動化和數位分析技術，能夠實現更嚴格的污染控制、更快的產品放行流程，並加強上游工程下游品質系統之間的協作。各組織機構日益認知到，偵測和定量技術不僅是實驗室工具，更是保障產品安全、最佳化批次週轉和滿足更高監管要求的策略性槓桿。

在實務中，這意味著跨職能團隊必須協調檢測方法的選擇、樣本處理流程和資料管治，才能獲得可重複且審核的結果。實驗室負責人必須平衡通量和靈敏度，根據既定標準檢驗新型平台，並在不影響可追溯性的前提下設計可擴展的工作流程。此外，次世代定序、數位PCR、免疫檢測平台和基於CRISPR的檢測工具的融合，不僅拓展了分析選擇，為加快生物製品上市速度創造了機遇，同時也對生物資訊學、檢測合格和污染風險管理提出了新的要求。

隨著生物技術研發管線向基因療法、病毒載體和複雜生物製藥等領域多元化發展，檢測和定量技術將日益影響生產週期、監管申報和病患安全預期。因此，對於致力於品質和營運韌性的現代生物製造企業而言，策略性地採用這些技術至關重要。

CRISPR、數位PCR、次世代定序和自動化技術的整合正在從根本上重塑病毒檢測工作流程、品質控制策略和監管準備。

技術創新、監管重點和生物製造領域不斷演變的應用案例的融合，正在重塑病毒檢測和定量格局。諸如基於 CRISPR 的檢測平台和數位 PCR 等快速成熟的技術，能夠以適用於高純度環境的形式提供單分子靈敏度；而次世代定序平台則提供全面的基因組分析能力，從而革新根本原因分析和病毒安全性檢測。同時，免疫檢測技術的改進和側向層析技術的創新，持續為常規監測提供經濟高效的高通量篩檢方案。

隨著產業領導企業逐漸拋棄傳統方法，他們正將儀器、試劑和軟體整合到以自動化、資料完整性和可追溯性為優先的整合工作流程中。這項轉變的驅動力在於監管機構日益重視健全的病毒安全計畫和可追溯的分析記錄，從而鼓勵對檢驗的平台和標準化通訊協定進行投資。同時，個人化醫療和基因療法的興起也加速了高靈敏度分子檢測工具的應用，因為它們引入了複雜的樣本基質和低豐度靶標，對傳統檢測方法提出了挑戰。

這些變革共同推動了一種新的營運模式，在這種模式下，分析決策與製造設計、品管策略和供應鏈規劃緊密結合。那些透過投資早期驗證、多學科培訓和整合分析來利用這些變革的組織，將能夠降低風險、提高批次放行效率，並在日益嚴格的法規環境下保持合規性。

評估美國分級關稅對關鍵資產採購、供應商資格認證和供應鏈韌性的營運和策略影響

美國將於2025年開始實施的累積關稅，使病毒檢測和定量所需的儀器、試劑和專用耗材的籌資策略變得更加複雜。這些關稅提高了進口診斷平台和某些試劑的相對成本，迫使採購團隊重新評估其供應商組合、庫存政策和資格認證流程。因此，製造商和實驗室需要在短期成本壓力與維持檢驗的工作流程和關鍵材料不間斷供應之間尋求平衡。

為此，各組織正採取多種緩解措施。我們看到，各組織正加快對符合性能和監管文件要求的替代供應商（例如區域製造商和契約製造製造商）的資格認證。我們也看到，各組織正致力於重新設計高風險耗材的供應鏈契約，以納入更長的前置作業時間和戰略庫存緩衝，同時優先考慮那些提供靈活交貨條款的契約。此外，各組織越來越關注透過試劑形式整合和平台整合來減少需要跨境運輸的SKU種類，這可以簡化關稅合規流程並降低物流成本。

從策略角度來看，關稅導致的成本轉移迫使產業相關人員加強供應商檢驗流程、擴大技術轉移能力，並投資於能夠容納在地採購試劑的模組化平台。中期來看，這些調整可能有助於減少對單一供應來源的依賴並提高韌性，但短期內，需要謹慎的變更管理、檢驗計劃以及相關人員的協作，以避免對生產計劃和產品品質保證造成干擾。

將儀器、試劑生態系統、技術、應用、最終用戶和檢體類型連結起來，進行全面的細分分析，從而實現策略性的檢測選擇和採購。

產品細分洞察表明，決策越來越依賴分析能力與特定應用需求的匹配。儀器和系統涵蓋 CRISPR 檢測系統、數位 PCR 系統、免疫檢測分析儀、次世代定序平台、即時PCR系統和聚合酵素連鎖反應熱迴圈儀，每種產品在靈敏度、通量和整合度方面都各具特色。試劑和套件包括免疫檢測試劑、NGS樣品製備試劑套件、PCR 預混液、RNA 萃取試劑套件和定序試劑，所有這些都是確保檢測一致性和批間可重複性的關鍵要素。軟體和服務則透過提供資料管理、演算法解讀和檢驗支持，完善了產品體系，滿足了受監管環境的需求。

從技術面來看，CRISPR技術、免疫檢測、次世代定序和聚合酵素鏈鎖反應（PCR）各有優缺點。免疫檢測包括化學發光免疫檢測、化學冷光免疫吸附試驗（ELISA）和橫向流動化驗等多種方法，其優點在於高通量和易用性，適用於篩檢。新一代定序方法，例如Illumina測序、Ion Torrent測序和奈米孔測序，可提供詳細的基因組資訊，用於表徵和根本原因分析。聚合酵素鏈鎖反應技術涵蓋了從傳統PCR到數位PCR和即時PCR等多種類型，每種技術都針對不同的靈敏度和定量需求。

應用細分突顯了基因治療品管、研究應用、疫苗開發、病毒量監測和病毒安全性檢測等用例，這些應用需求直接決定了合適的產品和技術組合。最終用戶，包括學術研究機構、受託研究機構(CRO)、診斷實驗室、醫院/診所和製藥/生物技術公司，各自擁有獨特的營運限制和監管要求，這些因素影響採購標準。此外，檢體類型，例如血液/血漿、環境樣本、呼吸道樣本和組織樣本，也帶來了分析方面的挑戰，這些挑戰決定了提取通訊協定、檢測方法的選擇和驗證途徑。理解這些相互關聯的細分層面，有助於制定更有針對性的平台選擇和籌資策略，以滿足績效要求和監管規定。

美洲、歐洲、中東和非洲以及亞太地區不同的區域促進因素如何影響偵測能力的取得、檢驗和供應鏈策略？

區域趨勢正在影響病毒檢測和定量能力的需求模式和供應鏈策略。在美洲，創新中心和密集的合約研發生產機構 (CDMO) 網路正在推動對高通量平台、先進定序和高精度定量方法的需求，以支援生物製藥研發管線。該地區還優先考慮快速明確的監管政策和營運擴充性，這影響供應商的選擇和驗證時間表。

在歐洲、中東和非洲地區，強大的公共衛生基礎設施和卓越的學術水平，以及監管協調方面的挑戰，持續推動對研究級和符合GMP規範的分析解決方案的需求。該地區的機構正在投資模組化實驗室自動化和協同檢驗框架，以滿足多樣化的監管要求，同時保持跨境互通性。在亞太地區，產能的快速擴張、不斷成長的生物製藥生產基地以及對本地生產能力的大規模投資，催生了對經濟高效的試劑、適應性強的平台和可擴展軟體解決方案的需求。亞太地區的供應鏈策略日益重視在地採購和區域夥伴關係，以最佳化成本並降低受國際貿易政策波動的影響。

這些區域差異總體上會影響供應商網路設計、驗證策略以及國內採購與國際採購等方面的決策。監管要求和基礎設施成熟度的區域差異要求製造商和實驗室根據當地的實際情況調整分析策略，以確保專案的連續性、合規性和時效性。

儀器製造商、試劑專家和平台創新者之間的策略競爭正在影響夥伴關係、驗證服務和長期採購決策。

病毒檢測和定量生態系統的競爭動態呈現成熟儀器供應商、試劑專家和新興平台創新者並存的態勢。大型儀器製造商持續投資於平台融合，整合分子、定序、免疫檢測和其他檢測方式，以提供更廣泛的分析功能，從而吸引科研和受監管的生產客戶。同時，專業的試劑和套件供應商則專注於配方一致性、批次控制和法規文件，以支援GMP環境下的檢驗工作流程。Start-Ups和規模化企業正不斷突破界限，利用基於CRISPR的檢測方法、改進的奈米孔定序技術和軟體驅動的分析技術，力求更快解決問題並提供更具實用價值的資料集。

硬體供應商、試劑生產商和軟體開發人員之間的合作日益普遍，從而能夠提供端到端的解決方案，降低終端用戶的使用複雜性。與受託研究機構(CRO) 和合約開發與生產組織 (CDMO) 建立策略合作夥伴關係，也有助於進行實際驗證工作，並加速產品在商業生產環境中的部署。能夠提供全面驗證方案、快速回應的技術支援和雲端資料管理的供應商，在客戶評估總體擁有成本和長期合規性時，往往能夠獲得競爭優勢。

最終，那些能夠平衡平台性能和可維護性、監管支援以及供應連續性的公司，將最有希望贏得長期合約。能夠快速回應變更管理請求、提供靈活的供應安排並展現出對互通軟體生態系統投資的供應商，將更能成功地滿足生物製造利害關係人不斷變化的需求。

針對生物製造企業領導者，提出具體且切實有效的建議，以加強檢測驗證、供應商多元化、自動化互通性和監管資料完整性。

產業領導者應優先考慮一系列切實可行的舉措，以提升病毒檢測和定量項目的分析穩健性、供應鏈韌性和監管合規性。首先，建立跨職能的管治，協調品管、生產製造和分析開發團隊，可以打破部門壁壘，加速檢測方法選擇、變更管理和技術轉移的決策。儘早將負責人融入檢驗計劃，可確保偵測效能標準符合放行要求，並減少後續環節可能出現的意外問題。

其次，各機構應使其合格供應商名單多元化，為關鍵試劑和耗材尋求冗餘，並建立清晰的重新認證流程，以最大限度地減少生產中斷。策略性庫存管理，結合基於情境的供應商連續性壓力測試，可以在不增加儲存成本的情況下降低營運風險。第三，投資於跨平台互通性和模組化自動化可以減少儀器和試劑規格切換時的摩擦，從而能夠靈活應對供應衝擊和法規變化。透過檢驗的軟體、完善的審核追蹤和標準化的報告範本來確保資料完整性，可以進一步提高監管可信度和審核準備度。

最後，透過與外部實驗室和合約機構合作，提升檢測能力，並在關鍵放行檢測中逐步引入數位PCR和標靶定序等靈敏度技術，將提高檢測靈敏度和診斷解析度。這些建議的綜合實施將建構一個穩健、合規且有效率的分析基礎設施，在保障產品品質的同時，加速專案開發進程。

採用嚴謹的混合調查方法，結合相關利益者訪談、技術文獻綜述、監管協調和基於情境的供應鏈分析。

本分析的調查方法系統地整合了定性和定量證據，以提供可靠且具有實踐意義的觀點。關鍵資訊是透過對實驗室主任、品質保證人員、採購經理和技術專家的訪談收集的，從而深入了解平台性能、驗證挑戰和供應商趨勢。這些第一手資料經過綜合分析，旨在識別不同終端使用者和應用領域面臨的通用挑戰和推動因素。

我們從同行評審文獻、監管指導文件、技術白皮書和公開產品文件中收集了二手資訊，以檢驗技術能力和典型應用場景。分析還包括基於場景的供應鏈評估，以根據行業標準的供應連續性實踐評估關稅變化和供應商中斷可能造成的營運影響。透過將定性研究結果與已記錄的產品規格、監管要求以及受法規環境中常用的驗證通訊協定進行交叉檢驗，確保了分析的嚴謹性。

在整個研究過程中，我們始終強調假設的透明度、記錄支持論點的可追溯證據，以及與生物製造企業面臨的實際實施限制保持一致。這種混合方法確保了結論和建議既有證據支持，也能直接應用於商業決策。

權威的綜合分析重點闡述了綜合檢測策略、供應商韌性和先進分析技術如何決定生物製造的成功和監管準備。

總之，病毒檢測和定量不再是輔助性活動，而是生物製造品質和運作策略的核心要素。靈敏的分子工具、自動化工作流程和先進分析技術的整合，正在切實改善污染控制、批次放行流程和監管可追溯性。同時，貿易政策趨勢和日益複雜的供應鏈也要求企業加強對供應商合格、靈活的驗證方案和互通平台的投資，以保障業務永續營運。

採取策略性方法的組織——結合跨職能管治、多元化採購、有針對性地應用敏感技術以及檢驗的資料管理系統——將更有利於管理風險並加快產品開發週期。隨著技術的不斷發展，持續學習、夥伴關係主導的檢驗活動以及情境規劃對於維持合規性和競爭優勢至關重要。最終，能否將分析能力轉化為穩健的生產實踐，將決定哪些組織能夠持續為患者提供高品質的生物製藥和先進療法。

目錄

第1章：序言

第2章調查方法

第3章執行摘要

第4章 市場概覽

第5章 市場洞察

  • 整合數位PCR和次世代定序以提高大規模生物製程中病毒量定量分析的準確性
  • 引入基於人工智慧的即時病毒去除過程監控，以降低生物製造過程中的生物安全風險
  • 引入配備線上病毒檢測感測器的連續流生物反應器，以最佳化疫苗生產的規模化生產。
  • 為實現新型快速分子檢測方法在全球核准用於病毒污染監測，並正在進行監管協調工作。
  • 開發一種基於CRISPR技術的多重檢測方法，用於同時檢測生物製藥中的多種病毒污染物
  • 基於微流體的現場病毒定量診斷平台在分散式生技藥品生產監測的應用進展

第6章：美國關稅的累積影響，2025年

第7章：人工智慧的累積影響，2025年

8. 生物製造病毒檢測和定量市場（按產品分類）

  • 設備和系統
    • CRISPR檢測系統
    • 數位PCR系統
    • 免疫檢測分析儀
    • 次世代定序平台
    • 即時PCR系統
    • 聚合酵素連鎖反應熱迴圈儀
  • 試劑和套件
    • 免疫檢測試劑
    • 次世代定序樣品製備套件
    • PCR 預混液
    • RNA萃取試劑套件
    • 定序試劑
  • 軟體和服務

9. 生物製造病毒檢測和定量市場（按技術分類）

  • CRISPR技術
  • 免疫檢測
    • 化學冷光免疫檢測
    • ELISA
    • 橫向流動化驗
  • 次世代定序
    • Illumina定序
    • 離子流定序
    • 奈米孔定序
  • 聚合酵素鏈鎖反應
    • 常規PCR
    • 數位PCR
    • 即時PCR

第10章 生物製造領域病毒檢測與定量市場（依應用分類）

  • 基因治療的品管
  • 研究用途
  • 疫苗研發
  • 病毒量監測
  • 病毒安全性測試

第11章 生物製造領域病毒檢測與定量市場（依最終用戶分類）

  • 學術和研究機構
  • CRO（受託研究機構）
  • 診斷實驗室
  • 醫院和診所
  • 製藥和生物技術公司

12. 生物製造領域病毒檢測與定量市場（依檢體類型分類）

  • 血液/血漿
  • 環境樣品
  • 呼吸道檢體
  • 組織樣本

13. 各地區生物製造領域病毒檢測與定量市場

  • 美洲
    • 北美洲
    • 拉丁美洲
  • 歐洲、中東和非洲
    • 歐洲
    • 中東
    • 非洲
  • 亞太地區

第14章 生物製造領域病毒檢測與量化市場（依產業分類）

  • ASEAN
  • GCC
  • EU
  • BRICS
  • G7
  • NATO

15. 各國生物製造領域病毒檢測與量化市場

  • 美國
  • 加拿大
  • 墨西哥
  • 巴西
  • 英國
  • 德國
  • 法國
  • 俄羅斯
  • 義大利
  • 西班牙
  • 中國
  • 印度
  • 日本
  • 澳洲
  • 韓國

第16章 競爭格局

  • 2024年市佔率分析
  • FPNV定位矩陣，2024
  • 競爭分析
    • Thermo Fisher Scientific Inc.
    • Danaher Corporation
    • Merck KGaA
    • Roche Holding AG
    • QIAGEN NV
    • Illumina, Inc.
    • Agilent Technologies, Inc.
    • Bio-Rad Laboratories, Inc.
    • PerkinElmer, Inc.
    • Sartorius AG
Product Code: MRR-5C6F41F5AF8D

The Biomanufacturing Viral Detection & Quantification Market is projected to grow by USD 5.63 billion at a CAGR of 8.67% by 2032.

KEY MARKET STATISTICS
Base Year [2024] USD 2.89 billion
Estimated Year [2025] USD 3.14 billion
Forecast Year [2032] USD 5.63 billion
CAGR (%) 8.67%

An in-depth introduction to how advanced viral detection and quantification technologies are becoming foundational to modern biomanufacturing quality and operational resilience

The biomanufacturing environment that supports viral detection and quantification is undergoing rapid evolution as precision assays move from research benches into regulated production environments. Advances in molecular diagnostics, coupled with automation and digital analytics, are driving more robust contamination control, accelerated product release workflows, and tighter integration between upstream and downstream quality systems. Organizations increasingly recognize that detection and quantification technologies are not discrete laboratory tools but strategic levers to protect product safety, optimize batch turnaround, and satisfy intensified regulatory expectations.

In practice, this means cross-functional teams must harmonize assay selection, sample handling procedures, and data governance to achieve reproducible, auditable results. Lab leaders need to balance throughput with sensitivity, validate novel platforms against established benchmarks, and design workflows that scale without compromising traceability. Moreover, the convergence of next-generation sequencing, digital PCR, immunoassay platforms, and CRISPR-based detection tools is expanding analytical choices, creating opportunities to reduce time-to-release for biologics while demanding new competency in bioinformatics, assay qualification, and contamination risk management.

As biotechnology pipelines diversify into gene therapies, viral vectors, and complex biologics, detection and quantification practices will increasingly influence manufacturing cycle time, regulatory submissions, and patient safety expectations. Therefore, a strategic introduction to these technologies frames them as essential infrastructure for any modern biomanufacturing organization committed to quality and operational resilience.

How convergence of CRISPR, digital PCR, next-generation sequencing, and automation is fundamentally reshaping viral detection workflows, quality strategies, and regulatory readiness

The landscape of viral detection and quantification is being redefined by a confluence of technological innovation, regulatory emphasis, and evolving use cases within biomanufacturing. Rapidly maturing technologies such as CRISPR-based detection platforms and digital PCR are delivering single-molecule sensitivity in formats suitable for high-integrity environments, while next-generation sequencing platforms provide comprehensive genomic resolution that transforms root-cause analysis and viral safety testing. At the same time, immunoassay refinements and lateral flow innovations continue to offer cost-effective, high-throughput screening options for routine surveillance.

Transitioning from legacy approaches, industry leaders are integrating instruments, reagents, and software into cohesive workflows that prioritize automation, data integrity, and traceability. This shift is reinforced by regulatory agencies placing greater emphasis on robust viral safety programs and traceable analytical records, prompting investments in validated platforms and standardized protocols. Simultaneously, the rise of personalized medicines and gene therapies has introduced complex sample matrices and low-abundance targets that challenge conventional detection modalities, thereby accelerating adoption of highly sensitive molecular tools.

Taken together, these transformative shifts are driving a new operating paradigm in which analytical decisions are tightly coupled to manufacturing design, quality control strategies, and supply chain planning. Organizations that harness these shifts through early validation, cross-disciplinary training, and investment in integrated analytics are positioned to reduce risk, improve batch release efficiency, and sustain compliance in an increasingly demanding regulatory environment.

Evaluating the operational and strategic effects of layered United States tariff measures on procurement, supplier qualification, and supply chain resilience for critical detection assets

Cumulative tariff actions originating in the United States in 2025 have introduced layered complexity into sourcing strategies for instruments, reagents, and specialized consumables used in viral detection and quantification. The tariffs have increased the relative cost of imported diagnostic platforms and certain reagent classes, prompting procurement teams to reassess supplier portfolios, inventory policies, and qualification pathways. As a result, manufacturers and laboratories are balancing the trade-offs between near-term cost pressures and the imperative to maintain validated workflows and uninterrupted supply of critical materials.

In response, organizations are pursuing a variety of mitigation approaches. Some are accelerating qualification of alternative suppliers, including regional manufacturers and contract manufacturers that can meet performance and regulatory documentation requirements. Others are redesigning supply chain agreements to include longer lead times and strategic inventory buffers for high-risk consumables while prioritizing contracts with flexible delivery terms. Additionally, there is growing interest in consolidating reagent formats and platform convergence to reduce the diversity of SKUs that require cross-border movement, thereby simplifying compliance with tariff regimes and lowering logistical overhead.

From a strategic perspective, tariff-driven cost shifts are compelling industry stakeholders to strengthen supplier validation processes, expand technical transfer capabilities, and invest in modular platforms that can accommodate locally sourced reagents. Over the medium term, these adaptations may enhance resilience by reducing single-source dependencies, but in the near term they demand careful change control, revalidation planning, and stakeholder alignment to avoid disruptions to manufacturing timelines and product quality assurance.

Comprehensive segmentation insights connecting instruments, reagent ecosystems, technologies, applications, end users, and sample types to strategic assay selection and procurement

Insight into product segmentation reveals that decision-making is increasingly driven by the need to match analytical capability with application-specific requirements. Instrumentation and systems span CRISPR detection systems, digital PCR systems, immunoassay analyzers, next-generation sequencing platforms, real-time PCR systems, and thermal cyclers, each offering distinct performance profiles for sensitivity, throughput, and integration. Reagents and kits encompass immunoassay reagents, NGS library preparation kits, PCR master mixes, RNA extraction kits, and sequencing reagents, all of which are fundamental to assay consistency and lot-to-lot reproducibility. Software and services complete the product landscape by enabling data management, algorithmic interpretation, and validation support necessary for regulated contexts.

From a technology perspective, CRISPR technology, immunoassays, next-generation sequencing, and polymerase chain reaction approaches present divergent strengths and trade-offs. Immunoassays include chemiluminescent immunoassay, ELISA, and lateral flow assay variants that favor throughput and ease of use for screening, while next-generation sequencing modalities such as Illumina sequencing, Ion Torrent sequencing, and nanopore sequencing deliver granular genomic insights for characterization and root-cause analyses. Polymerase chain reaction techniques range from conventional PCR to digital PCR and real-time PCR, with each type serving different sensitivity and quantitation needs.

Application segmentation highlights use cases including gene therapy quality control, research applications, vaccine development, viral load monitoring, and viral safety testing, and these application needs directly influence which product and technology combinations are appropriate. End users such as academic and research institutions, contract research organizations, diagnostic laboratories, hospitals and clinics, and pharmaceutical and biotechnology companies each have distinct operational constraints and regulatory expectations that shape procurement criteria. Finally, sample types including blood and plasma, environmental samples, respiratory samples, and tissue samples impose analytical challenges that determine extraction protocols, assay selection, and validation pathways. Understanding these interconnected segmentation layers enables more targeted platform selection and procurement strategies that align with performance requirements and regulatory obligations.

How distinct regional drivers across the Americas, Europe Middle East & Africa, and Asia-Pacific are shaping procurement, validation, and supply chain strategies for detection capabilities

Regional dynamics are shaping both demand patterns and supply chain strategies for viral detection and quantification capabilities. In the Americas, innovation hubs and a dense network of contract development and manufacturing organizations drive demand for high-throughput platforms, advanced sequencing, and highly quantitative modalities that support complex biologics pipelines. This region also emphasizes rapid regulatory clarity and operational scalability, which influences supplier selection and validation timelines.

In Europe, the Middle East & Africa, regulatory harmonization challenges coexist with pockets of strong public health infrastructure and academic excellence that sustain demand for both research-grade and GMP-compliant analytical solutions. Organizations across this region are investing in modular laboratory automation and collaborative validation frameworks to meet diverse regulatory requirements while maintaining cross-border interoperability. In the Asia-Pacific region, rapid capacity expansion, a growing biopharmaceutical manufacturing base, and significant investment in local manufacturing capability are creating demand for cost-efficient reagents, adaptable platforms, and scalable software solutions. Supply chain strategies in Asia-Pacific often prioritize local sourcing and regional partnerships to optimize costs and reduce exposure to international trade policy shifts.

Taken together, these regional differentiators influence supplier network design, validation strategies, and decisions about onshoring versus international procurement. Because regulatory expectations and infrastructure maturity vary across these geographies, manufacturers and laboratories must align analytical strategies with regional operational realities to ensure continuity, compliance, and time-sensitive program delivery.

Strategic competitive dynamics among instrument leaders, reagent specialists, and platform innovators shaping partnerships, validation services, and long-term procurement decisions

Competitive dynamics in the viral detection and quantification ecosystem reflect a mix of established instrument providers, reagent specialists, and emerging platform innovators. Leading instrument makers continue to invest in platform convergence, integrating molecular, sequencing, and immunoassay modalities to offer broader analytical footprints that appeal to both research and regulated manufacturing customers. At the same time, specialized reagent and kit suppliers focus on formulation consistency, lot control, and regulatory documentation to support validated workflows in GMP environments. Startups and scale-ups are pushing boundaries with CRISPR-based assays, nanopore sequencing improvements, and software-driven analytics that promise faster problem resolution and more actionable datasets.

Partnerships between hardware vendors, reagent manufacturers, and software developers are increasingly common, enabling end-to-end solutions that reduce complexity for end users. Strategic alliances with contract research organizations and contract development and manufacturing organizations also facilitate hands-on validation work and accelerate adoption in commercial manufacturing settings. Vendors that provide comprehensive validation packages, responsive technical support, and cloud-enabled data management often gain a competitive edge when customers evaluate total cost of ownership alongside long-term regulatory commitments.

Ultimately, companies that balance platform performance with serviceability, regulatory support, and supply continuity are best positioned to win long-term engagements. Providers that demonstrate responsiveness to change control requests, offer flexible supply arrangements, and invest in interoperable software ecosystems will be more successful in meeting the evolving needs of biomanufacturing stakeholders.

Concrete, high-impact recommendations for biomanufacturing leaders to strengthen assay validation, supplier diversification, automation interoperability, and regulatory data integrity

Industry leaders should prioritize a set of actionable initiatives to strengthen analytical robustness, supply resilience, and regulatory preparedness across viral detection and quantification programs. First, instituting cross-functional governance that coordinates quality, manufacturing, and analytical development teams will reduce silos and accelerate decision-making for assay selection, change control, and technical transfers. Embedding subject matter experts in validation planning early ensures assay performance criteria are aligned with release requirements and mitigates downstream surprises.

Second, organizations should diversify qualified supplier lists and pursue redundancy for critical reagents and consumables while developing clear requalification pathways to minimize production disruptions. Strategic inventory governance, combined with scenario-based stress testing of supplier continuity, can reduce operational risk without inflating carrying costs. Third, investing in platform interoperability and modular automation reduces friction when swapping instruments or reagent formats, enabling more agile responses to supply shocks or regulatory changes. Ensuring data integrity through validated software, robust audit trails, and standardized reporting templates will further enhance regulatory confidence and inspection readiness.

Finally, cultivating partnerships with external laboratories and contract organizations for surge capacity, and pursuing incremental adoption of high-sensitivity techniques such as digital PCR and targeted sequencing for critical release assays, will improve sensitivity and diagnostic resolution. Executed together, these recommendations create a resilient, compliant, and efficient analytical foundation that supports accelerated program development while safeguarding product quality.

A rigorous mixed-methods research approach combining stakeholder interviews, technical literature synthesis, regulatory alignment, and scenario-based supply chain analysis

The research methodology underpinning this analysis integrates a structured mix of qualitative and quantitative evidence to deliver a robust, operationally relevant perspective. Primary inputs were gathered through targeted interviews with laboratory directors, quality assurance leaders, procurement managers, and technical subject matter experts who provided insights into platform performance, validation challenges, and supplier dynamics. These firsthand accounts were synthesized to identify common pain points and adoption drivers across different end users and applications.

Secondary information was compiled from peer-reviewed literature, regulatory guidance documents, technical white papers, and publicly available product documentation to validate technological capabilities and typical use-case scenarios. The analysis also included scenario-based supply chain assessments to evaluate the potential operational implications of tariff changes and supplier disruptions, informed by industry-standard supply continuity practices. Analytical rigor was maintained through cross-validation of qualitative findings against documented product specifications, regulatory expectations, and common validation protocols used in regulated environments.

Throughout the research cycle, emphasis was placed on transparency of assumptions, traceable evidence trails for assertions, and alignment with practical implementation constraints faced by biomanufacturing organizations. This mixed-methods approach ensures that the conclusions and recommendations are both evidence-based and directly applicable to operational decision-making.

A conclusive synthesis emphasizing how integrated detection strategies, supplier resilience, and advanced analytics will determine biomanufacturing success and regulatory readiness

In conclusion, viral detection and quantification are no longer ancillary activities but core elements of biomanufacturing quality and operational strategy. The integration of sensitive molecular tools, automated workflows, and advanced analytics is delivering tangible improvements in contamination control, batch release processes, and regulatory traceability. At the same time, trade policy developments and supply chain complexity require proactive supplier qualification, flexible validation planning, and investment in interoperable platforms to sustain uninterrupted operations.

Organizations that adopt a strategic approach-combining cross-functional governance, diversified procurement, targeted adoption of high-sensitivity techniques, and validated data management systems-will be better positioned to manage risk and accelerate product development cycles. As technologies continue to evolve, continuous learning, partnership-driven validation efforts, and scenario planning will be essential to maintaining both compliance and competitive advantage. Ultimately, the ability to translate analytical capability into robust manufacturing practice will determine which organizations consistently deliver high-quality biologics and advanced therapeutics to patients.

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Segmentation & Coverage
  • 1.3. Years Considered for the Study
  • 1.4. Currency & Pricing
  • 1.5. Language
  • 1.6. Stakeholders

2. Research Methodology

3. Executive Summary

4. Market Overview

5. Market Insights

  • 5.1. Integration of digital PCR and next-generation sequencing to enhance viral load quantification accuracy across large-scale bioprocesses
  • 5.2. Adoption of AI-enabled real-time monitoring of viral clearance steps to mitigate biosafety risks during biomanufacturing
  • 5.3. Implementation of continuous flow bioreactors with inline viral detection sensors to optimize vaccine production scalability
  • 5.4. Regulatory harmonization efforts for global approval of novel rapid molecular assays in viral contamination monitoring
  • 5.5. Development of multiplexed CRISPR-based assays for simultaneous detection of multiple viral contaminants in biologics
  • 5.6. Advances in microfluidic-based point-of-care viral quantification platforms for decentralized biologics manufacturing oversight

6. Cumulative Impact of United States Tariffs 2025

7. Cumulative Impact of Artificial Intelligence 2025

8. Biomanufacturing Viral Detection & Quantification Market, by Product

  • 8.1. Instruments & Systems
    • 8.1.1. Crispr Detection Systems
    • 8.1.2. Digital Pcr Systems
    • 8.1.3. Immunoassay Analyzers
    • 8.1.4. Ngs Platforms
    • 8.1.5. Real Time Pcr Systems
    • 8.1.6. Thermal Cyclers
  • 8.2. Reagents & Kits
    • 8.2.1. Immunoassay Reagents
    • 8.2.2. Ngs Library Preparation Kits
    • 8.2.3. Pcr Master Mixes
    • 8.2.4. Rna Extraction Kits
    • 8.2.5. Sequencing Reagents
  • 8.3. Software & Services

9. Biomanufacturing Viral Detection & Quantification Market, by Technology

  • 9.1. Crispr Technology
  • 9.2. Immunoassay
    • 9.2.1. Chemiluminescent Immunoassay
    • 9.2.2. Elisa
    • 9.2.3. Lateral Flow Assay
  • 9.3. Next Generation Sequencing
    • 9.3.1. Illumina Sequencing
    • 9.3.2. Ion Torrent Sequencing
    • 9.3.3. Nanopore Sequencing
  • 9.4. Polymerase Chain Reaction
    • 9.4.1. Conventional Pcr
    • 9.4.2. Digital Pcr
    • 9.4.3. Real-Time Pcr

10. Biomanufacturing Viral Detection & Quantification Market, by Application

  • 10.1. Gene Therapy Quality Control
  • 10.2. Research Applications
  • 10.3. Vaccine Development
  • 10.4. Viral Load Monitoring
  • 10.5. Viral Safety Testing

11. Biomanufacturing Viral Detection & Quantification Market, by End User

  • 11.1. Academic & Research Institutions
  • 11.2. Contract Research Organizations
  • 11.3. Diagnostic Laboratories
  • 11.4. Hospitals & Clinics
  • 11.5. Pharmaceutical & Biotechnology Companies

12. Biomanufacturing Viral Detection & Quantification Market, by Sample Type

  • 12.1. Blood & Plasma
  • 12.2. Environmental Samples
  • 12.3. Respiratory Samples
  • 12.4. Tissue Samples

13. Biomanufacturing Viral Detection & Quantification Market, by Region

  • 13.1. Americas
    • 13.1.1. North America
    • 13.1.2. Latin America
  • 13.2. Europe, Middle East & Africa
    • 13.2.1. Europe
    • 13.2.2. Middle East
    • 13.2.3. Africa
  • 13.3. Asia-Pacific

14. Biomanufacturing Viral Detection & Quantification Market, by Group

  • 14.1. ASEAN
  • 14.2. GCC
  • 14.3. European Union
  • 14.4. BRICS
  • 14.5. G7
  • 14.6. NATO

15. Biomanufacturing Viral Detection & Quantification Market, by Country

  • 15.1. United States
  • 15.2. Canada
  • 15.3. Mexico
  • 15.4. Brazil
  • 15.5. United Kingdom
  • 15.6. Germany
  • 15.7. France
  • 15.8. Russia
  • 15.9. Italy
  • 15.10. Spain
  • 15.11. China
  • 15.12. India
  • 15.13. Japan
  • 15.14. Australia
  • 15.15. South Korea

16. Competitive Landscape

  • 16.1. Market Share Analysis, 2024
  • 16.2. FPNV Positioning Matrix, 2024
  • 16.3. Competitive Analysis
    • 16.3.1. Thermo Fisher Scientific Inc.
    • 16.3.2. Danaher Corporation
    • 16.3.3. Merck KGaA
    • 16.3.4. Roche Holding AG
    • 16.3.5. QIAGEN N.V.
    • 16.3.6. Illumina, Inc.
    • 16.3.7. Agilent Technologies, Inc.
    • 16.3.8. Bio-Rad Laboratories, Inc.
    • 16.3.9. PerkinElmer, Inc.
    • 16.3.10. Sartorius AG

LIST OF FIGURES

  • FIGURE 1. GLOBAL BIOMANUFACTURING VIRAL DETECTION & QUANTIFICATION MARKET SIZE, 2018-2032 (USD MILLION)
  • FIGURE 2. GLOBAL BIOMANUFACTURING VIRAL DETECTION & QUANTIFICATION MARKET SIZE, BY PRODUCT, 2024 VS 2032 (%)
  • FIGURE 3. GLOBAL BIOMANUFACTURING VIRAL DETECTION & QUANTIFICATION MARKET SIZE, BY PRODUCT, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 4. GLOBAL BIOMANUFACTURING VIRAL DETECTION & QUANTIFICATION MARKET SIZE, BY TECHNOLOGY, 2024 VS 2032 (%)
  • FIGURE 5. GLOBAL BIOMANUFACTURING VIRAL DETECTION & QUANTIFICATION MARKET SIZE, BY TECHNOLOGY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 6. GLOBAL BIOMANUFACTURING VIRAL DETECTION & QUANTIFICATION MARKET SIZE, BY APPLICATION, 2024 VS 2032 (%)
  • FIGURE 7. GLOBAL BIOMANUFACTURING VIRAL DETECTION & QUANTIFICATION MARKET SIZE, BY APPLICATION, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 8. GLOBAL BIOMANUFACTURING VIRAL DETECTION & QUANTIFICATION MARKET SIZE, BY END USER, 2024 VS 2032 (%)
  • FIGURE 9. GLOBAL BIOMANUFACTURING VIRAL DETECTION & QUANTIFICATION MARKET SIZE, BY END USER, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 10. GLOBAL BIOMANUFACTURING VIRAL DETECTION & QUANTIFICATION MARKET SIZE, BY SAMPLE TYPE, 2024 VS 2032 (%)
  • FIGURE 11. GLOBAL BIOMANUFACTURING VIRAL DETECTION & QUANTIFICATION MARKET SIZE, BY SAMPLE TYPE, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 12. GLOBAL BIOMANUFACTURING VIRAL DETECTION & QUANTIFICATION MARKET SIZE, BY REGION, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 13. AMERICAS BIOMANUFACTURING VIRAL DETECTION & QUANTIFICATION MARKET SIZE, BY SUBREGION, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 14. NORTH AMERICA BIOMANUFACTURING VIRAL DETECTION & QUANTIFICATION MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 15. LATIN AMERICA BIOMANUFACTURING VIRAL DETECTION & QUANTIFICATION MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 16. EUROPE, MIDDLE EAST & AFRICA BIOMANUFACTURING VIRAL DETECTION & QUANTIFICATION MARKET SIZE, BY SUBREGION, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 17. EUROPE BIOMANUFACTURING VIRAL DETECTION & QUANTIFICATION MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 18. MIDDLE EAST BIOMANUFACTURING VIRAL DETECTION & QUANTIFICATION MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 19. AFRICA BIOMANUFACTURING VIRAL DETECTION & QUANTIFICATION MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 20. ASIA-PACIFIC BIOMANUFACTURING VIRAL DETECTION & QUANTIFICATION MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 21. GLOBAL BIOMANUFACTURING VIRAL DETECTION & QUANTIFICATION MARKET SIZE, BY GROUP, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 22. ASEAN BIOMANUFACTURING VIRAL DETECTION & QUANTIFICATION MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 23. GCC BIOMANUFACTURING VIRAL DETECTION & QUANTIFICATION MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 24. EUROPEAN UNION BIOMANUFACTURING VIRAL DETECTION & QUANTIFICATION MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 25. BRICS BIOMANUFACTURING VIRAL DETECTION & QUANTIFICATION MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 26. G7 BIOMANUFACTURING VIRAL DETECTION & QUANTIFICATION MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 27. NATO BIOMANUFACTURING VIRAL DETECTION & QUANTIFICATION MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 28. GLOBAL BIOMANUFACTURING VIRAL DETECTION & QUANTIFICATION MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 29. BIOMANUFACTURING VIRAL DETECTION & QUANTIFICATION MARKET SHARE, BY KEY PLAYER, 2024
  • FIGURE 30. BIOMANUFACTURING VIRAL DETECTION & QUANTIFICATION MARKET, FPNV POSITIONING MATRIX, 2024

LIST OF TABLES

  • TABLE 1. BIOMANUFACTURING VIRAL DETECTION & QUANTIFICATION MARKET SEGMENTATION & COVERAGE
  • TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2018-2024
  • TABLE 3. GLOBAL BIOMANUFACTURING VIRAL DETECTION & QUANTIFICATION MARKET SIZE, 2018-2024 (USD MILLION)
  • TABLE 4. GLOBAL BIOMANUFACTURING VIRAL DETECTION & QUANTIFICATION MARKET SIZE, 2025-2032 (USD MILLION)
  • TABLE 5. GLOBAL BIOMANUFACTURING VIRAL DETECTION & QUANTIFICATION MARKET SIZE, BY PRODUCT, 2018-2024 (USD MILLION)
  • TABLE 6. GLOBAL BIOMANUFACTURING VIRAL DETECTION & QUANTIFICATION MARKET SIZE, BY PRODUCT, 2025-2032 (USD MILLION)
  • TABLE 7. GLOBAL BIOMANUFACTURING VIRAL DETECTION & QUANTIFICATION MARKET SIZE, BY INSTRUMENTS & SYSTEMS, 2018-2024 (USD MILLION)
  • TABLE 8. GLOBAL BIOMANUFACTURING VIRAL DETECTION & QUANTIFICATION MARKET SIZE, BY INSTRUMENTS & SYSTEMS, 2025-2032 (USD MILLION)
  • TABLE 9. GLOBAL BIOMANUFACTURING VIRAL DETECTION & QUANTIFICATION MARKET SIZE, BY INSTRUMENTS & SYSTEMS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 10. GLOBAL BIOMANUFACTURING VIRAL DETECTION & QUANTIFICATION MARKET SIZE, BY INSTRUMENTS & SYSTEMS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 11. GLOBAL BIOMANUFACTURING VIRAL DETECTION & QUANTIFICATION MARKET SIZE, BY INSTRUMENTS & SYSTEMS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 12. GLOBAL BIOMANUFACTURING VIRAL DETECTION & QUANTIFICATION MARKET SIZE, BY INSTRUMENTS & SYSTEMS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 13. GLOBAL BIOMANUFACTURING VIRAL DETECTION & QUANTIFICATION MARKET SIZE, BY INSTRUMENTS & SYSTEMS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 14. GLOBAL BIOMANUFACTURING VIRAL DETECTION & QUANTIFICATION MARKET SIZE, BY INSTRUMENTS & SYSTEMS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 15. GLOBAL BIOMANUFACTURING VIRAL DETECTION & QUANTIFICATION MARKET SIZE, BY CRISPR DETECTION SYSTEMS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 16. GLOBAL BIOMANUFACTURING VIRAL DETECTION & QUANTIFICATION MARKET SIZE, BY CRISPR DETECTION SYSTEMS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 17. GLOBAL BIOMANUFACTURING VIRAL DETECTION & QUANTIFICATION MARKET SIZE, BY CRISPR DETECTION SYSTEMS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 18. GLOBAL BIOMANUFACTURING VIRAL DETECTION & QUANTIFICATION MARKET SIZE, BY CRISPR DETECTION SYSTEMS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 19. GLOBAL BIOMANUFACTURING VIRAL DETECTION & QUANTIFICATION MARKET SIZE, BY CRISPR DETECTION SYSTEMS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 20. GLOBAL BIOMANUFACTURING VIRAL DETECTION & QUANTIFICATION MARKET SIZE, BY CRISPR DETECTION SYSTEMS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 21. GLOBAL BIOMANUFACTURING VIRAL DETECTION & QUANTIFICATION MARKET SIZE, BY DIGITAL PCR SYSTEMS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 22. GLOBAL BIOMANUFACTURING VIRAL DETECTION & QUANTIFICATION MARKET SIZE, BY DIGITAL PCR SYSTEMS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 23. GLOBAL BIOMANUFACTURING VIRAL DETECTION & QUANTIFICATION MARKET SIZE, BY DIGITAL PCR SYSTEMS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 24. GLOBAL BIOMANUFACTURING VIRAL DETECTION & QUANTIFICATION MARKET SIZE, BY DIGITAL PCR SYSTEMS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 25. GLOBAL BIOMANUFACTURING VIRAL DETECTION & QUANTIFICATION MARKET SIZE, BY DIGITAL PCR SYSTEMS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 26. GLOBAL BIOMANUFACTURING VIRAL DETECTION & QUANTIFICATION MARKET SIZE, BY DIGITAL PCR SYSTEMS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 27. GLOBAL BIOMANUFACTURING VIRAL DETECTION & QUANTIFICATION MARKET SIZE, BY IMMUNOASSAY ANALYZERS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 28. GLOBAL BIOMANUFACTURING VIRAL DETECTION & QUANTIFICATION MARKET SIZE, BY IMMUNOASSAY ANALYZERS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 29. GLOBAL BIOMANUFACTURING VIRAL DETECTION & QUANTIFICATION MARKET SIZE, BY IMMUNOASSAY ANALYZERS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 30. GLOBAL BIOMANUFACTURING VIRAL DETECTION & QUANTIFICATION MARKET SIZE, BY IMMUNOASSAY ANALYZERS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 31. GLOBAL BIOMANUFACTURING VIRAL DETECTION & QUANTIFICATION MARKET SIZE, BY IMMUNOASSAY ANALYZERS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 32. GLOBAL BIOMANUFACTURING VIRAL DETECTION & QUANTIFICATION MARKET SIZE, BY IMMUNOASSAY ANALYZERS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 33. GLOBAL BIOMANUFACTURING VIRAL DETECTION & QUANTIFICATION MARKET SIZE, BY NGS PLATFORMS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 34. GLOBAL BIOMANUFACTURING VIRAL DETECTION & QUANTIFICATION MARKET SIZE, BY NGS PLATFORMS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 35. GLOBAL BIOMANUFACTURING VIRAL DETECTION & QUANTIFICATION MARKET SIZE, BY NGS PLATFORMS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 36. GLOBAL BIOMANUFACTURING VIRAL DETECTION & QUANTIFICATION MARKET SIZE, BY NGS PLATFORMS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 37. GLOBAL BIOMANUFACTURING VIRAL DETECTION & QUANTIFICATION MARKET SIZE, BY NGS PLATFORMS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 38. GLOBAL BIOMANUFACTURING VIRAL DETECTION & QUANTIFICATION MARKET SIZE, BY NGS PLATFORMS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 39. GLOBAL BIOMANUFACTURING VIRAL DETECTION & QUANTIFICATION MARKET SIZE, BY REAL TIME PCR SYSTEMS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 40. GLOBAL BIOMANUFACTURING VIRAL DETECTION & QUANTIFICATION MARKET SIZE, BY REAL TIME PCR SYSTEMS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 41. GLOBAL BIOMANUFACTURING VIRAL DETECTION & QUANTIFICATION MARKET SIZE, BY REAL TIME PCR SYSTEMS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 42. GLOBAL BIOMANUFACTURING VIRAL DETECTION & QUANTIFICATION MARKET SIZE, BY REAL TIME PCR SYSTEMS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 43. GLOBAL BIOMANUFACTURING VIRAL DETECTION & QUANTIFICATION MARKET SIZE, BY REAL TIME PCR SYSTEMS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 44. GLOBAL BIOMANUFACTURING VIRAL DETECTION & QUANTIFICATION MARKET SIZE, BY REAL TIME PCR SYSTEMS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 45. GLOBAL BIOMANUFACTURING VIRAL DETECTION & QUANTIFICATION MARKET SIZE, BY THERMAL CYCLERS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 46. GLOBAL BIOMANUFACTURING VIRAL DETECTION & QUANTIFICATION MARKET SIZE, BY THERMAL CYCLERS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 47. GLOBAL BIOMANUFACTURING VIRAL DETECTION & QUANTIFICATION MARKET SIZE, BY THERMAL CYCLERS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 48. GLOBAL BIOMANUFACTURING VIRAL DETECTION & QUANTIFICATION MARKET SIZE, BY THERMAL CYCLERS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 49. GLOBAL BIOMANUFACTURING VIRAL DETECTION & QUANTIFICATION MARKET SIZE, BY THERMAL CYCLERS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 50. GLOBAL BIOMANUFACTURING VIRAL DETECTION & QUANTIFICATION MARKET SIZE, BY THERMAL CYCLERS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 51. GLOBAL BIOMANUFACTURING VIRAL DETECTION & QUANTIFICATION MARKET SIZE, BY REAGENTS & KITS, 2018-2024 (USD MILLION)
  • TABLE 52. GLOBAL BIOMANUFACTURING VIRAL DETECTION & QUANTIFICATION MARKET SIZE, BY REAGENTS & KITS, 2025-2032 (USD MILLION)
  • TABLE 53. GLOBAL BIOMANUFACTURING VIRAL DETECTION & QUANTIFICATION MARKET SIZE, BY REAGENTS & KITS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 54. GLOBAL BIOMANUFACTURING VIRAL DETECTION & QUANTIFICATION MARKET SIZE, BY REAGENTS & KITS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 55. GLOBAL BIOMANUFACTURING VIRAL DETECTION & QUANTIFICATION MARKET SIZE, BY REAGENTS & KITS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 56. GLOBAL BIOMANUFACTURING VIRAL DETECTION & QUANTIFICATION MARKET SIZE, BY REAGENTS & KITS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 57. GLOBAL BIOMANUFACTURING VIRAL DETECTION & QUANTIFICATION MARKET SIZE, BY REAGENTS & KITS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 58. GLOBAL BIOMANUFACTURING VIRAL DETECTION & QUANTIFICATION MARKET SIZE, BY REAGENTS & KITS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 59. GLOBAL BIOMANUFACTURING VIRAL DETECTION & QUANTIFICATION MARKET SIZE, BY IMMUNOASSAY REAGENTS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 60. GLOBAL BIOMANUFACTURING VIRAL DETECTION & QUANTIFICATION MARKET SIZE, BY IMMUNOASSAY REAGENTS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 61. GLOBAL BIOMANUFACTURING VIRAL DETECTION & QUANTIFICATION MARKET SIZE, BY IMMUNOASSAY REAGENTS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 62. GLOBAL BIOMANUFACTURING VIRAL DETECTION & QUANTIFICATION MARKET SIZE, BY IMMUNOASSAY REAGENTS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 63. GLOBAL BIOMANUFACTURING VIRAL DETECTION & QUANTIFICATION MARKET SIZE, BY IMMUNOASSAY REAGENTS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 64. GLOBAL BIOMANUFACTURING VIRAL DETECTION & QUANTIFICATION MARKET SIZE, BY IMMUNOASSAY REAGENTS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 65. GLOBAL BIOMANUFACTURING VIRAL DETECTION & QUANTIFICATION MARKET SIZE, BY NGS LIBRARY PREPARATION KITS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 66. GLOBAL BIOMANUFACTURING VIRAL DETECTION & QUANTIFICATION MARKET SIZE, BY NGS LIBRARY PREPARATION KITS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 67. GLOBAL BIOMANUFACTURING VIRAL DETECTION & QUANTIFICATION MARKET SIZE, BY NGS LIBRARY PREPARATION KITS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 68. GLOBAL BIOMANUFACTURING VIRAL DETECTION & QUANTIFICATION MARKET SIZE, BY NGS LIBRARY PREPARATION KITS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 69. GLOBAL BIOMANUFACTURING VIRAL DETECTION & QUANTIFICATION MARKET SIZE, BY NGS LIBRARY PREPARATION KITS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 70. GLOBAL BIOMANUFACTURING VIRAL DETECTION & QUANTIFICATION MARKET SIZE, BY NGS LIBRARY PREPARATION KITS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 71. GLOBAL BIOMANUFACTURING VIRAL DETECTION & QUANTIFICATION MARKET SIZE, BY PCR MASTER MIXES, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 72. GLOBAL BIOMANUFACTURING VIRAL DETECTION & QUANTIFICATION MARKET SIZE, BY PCR MASTER MIXES, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 73. GLOBAL BIOMANUFACTURING VIRAL DETECTION & QUANTIFICATION MARKET SIZE, BY PCR MASTER MIXES, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 74. GLOBAL BIOMANUFACTURING VIRAL DETECTION & QUANTIFICATION MARKET SIZE, BY PCR MASTER MIXES, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 75. GLOBAL BIOMANUFACTURING VIRAL DETECTION & QUANTIFICATION MARKET SIZE, BY PCR MASTER MIXES, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 76. GLOBAL BIOMANUFACTURING VIRAL DETECTION & QUANTIFICATION MARKET SIZE, BY PCR MASTER MIXES, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 77. GLOBAL BIOMANUFACTURING VIRAL DETECTION & QUANTIFICATION MARKET SIZE, BY RNA EXTRACTION KITS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 78. GLOBAL BIOMANUFACTURING VIRAL DETECTION & QUANTIFICATION MARKET SIZE, BY RNA EXTRACTION KITS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 79. GLOBAL BIOMANUFACTURING VIRAL DETECTION & QUANTIFICATION MARKET SIZE, BY RNA EXTRACTION KITS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 80. GLOBAL BIOMANUFACTURING VIRAL DETECTION & QUANTIFICATION MARKET SIZE, BY RNA EXTRACTION KITS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 81. GLOBAL BIOMANUFACTURING VIRAL DETECTION & QUANTIFICATION MARKET SIZE, BY RNA EXTRACTION KITS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 82. GLOBAL BIOMANUFACTURING VIRAL DETECTION & QUANTIFICATION MARKET SIZE, BY RNA EXTRACTION KITS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 83. GLOBAL BIOMANUFACTURING VIRAL DETECTION & QUANTIFICATION MARKET SIZE, BY SEQUENCING REAGENTS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 84. GLOBAL BIOMANUFACTURING VIRAL DETECTION & QUANTIFICATION MARKET SIZE, BY SEQUENCING REAGENTS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 85. GLOBAL BIOMANUFACTURING VIRAL DETECTION & QUANTIFICATION MARKET SIZE, BY SEQUENCING REAGENTS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 86. GLOBAL BIOMANUFACTURING VIRAL DETECTION & QUANTIFICATION MARKET SIZE, BY SEQUENCING REAGENTS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 87. GLOBAL BIOMANUFACTURING VIRAL DETECTION & QUANTIFICATION MARKET SIZE, BY SEQUENCING REAGENTS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 88. GLOBAL BIOMANUFACTURING VIRAL DETECTION & QUANTIFICATION MARKET SIZE, BY SEQUENCING REAGENTS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 89. GLOBAL BIOMANUFACTURING VIRAL DETECTION & QUANTIFICATION MARKET SIZE, BY SOFTWARE & SERVICES, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 90. GLOBAL BIOMANUFACTURING VIRAL DETECTION & QUANTIFICATION MARKET SIZE, BY SOFTWARE & SERVICES, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 91. GLOBAL BIOMANUFACTURING VIRAL DETECTION & QUANTIFICATION MARKET SIZE, BY SOFTWARE & SERVICES, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 92. GLOBAL BIOMANUFACTURING VIRAL DETECTION & QUANTIFICATION MARKET SIZE, BY SOFTWARE & SERVICES, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 93. GLOBAL BIOMANUFACTURING VIRAL DETECTION & QUANTIFICATION MARKET SIZE, BY SOFTWARE & SERVICES, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 94. GLOBAL BIOMANUFACTURING VIRAL DETECTION & QUANTIFICATION MARKET SIZE, BY SOFTWARE & SERVICES, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 95. GLOBAL BIOMANUFACTURING VIRAL DETECTION & QUANTIFICATION MARKET SIZE, BY TECHNOLOGY, 2018-2024 (USD MILLION)
  • TABLE 96. GLOBAL BIOMANUFACTURING VIRAL DETECTION & QUANTIFICATION MARKET SIZE, BY TECHNOLOGY, 2025-2032 (USD MILLION)
  • TABLE 97. GLOBAL BIOMANUFACTURING VIRAL DETECTION & QUANTIFICATION MARKET SIZE, BY CRISPR TECHNOLOGY, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 98. GLOBAL BIOMANUFACTURING VIRAL DETECTION & QUANTIFICATION MARKET SIZE, BY CRISPR TECHNOLOGY, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 99. GLOBAL BIOMANUFACTURING VIRAL DETECTION & QUANTIFICATION MARKET SIZE, BY CRISPR TECHNOLOGY, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 100. GLOBAL BIOMANUFACTURING VIRAL DETECTION & QUANTIFICATION MARKET SIZE, BY CRISPR TECHNOLOGY, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 101. GLOBAL BIOMANUFACTURING VIRAL DETECTION & QUANTIFICATION MARKET SIZE, BY CRISPR TECHNOLOGY, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 102. GLOBAL BIOMANUFACTURING VIRAL DETECTION & QUANTIFICATION MARKET SIZE, BY CRISPR TECHNOLOGY, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 103. GLOBAL BIOMANUFACTURING VIRAL DETECTION & QUANTIFICATION MARKET SIZE, BY IMMUNOASSAY, 2018-2024 (USD MILLION)
  • TABLE 104. GLOBAL BIOMANUFACTURING VIRAL DETECTION & QUANTIFICATION MARKET SIZE, BY IMMUNOASSAY, 2025-2032 (USD MILLION)
  • TABLE 105. GLOBAL BIOMANUFACTURING VIRAL DETECTION & QUANTIFICATION MARKET SIZE, BY IMMUNOASSAY, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 106. GLOBAL BIOMANUFACTURING VIRAL DETECTION & QUANTIFICATION MARKET SIZE, BY IMMUNOASSAY, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 107. GLOBAL BIOMANUFACTURING VIRAL DETECTION & QUANTIFICATION MARKET SIZE, BY IMMUNOASSAY, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 108. GLOBAL BIOMANUFACTURING VIRAL DETECTION & QUANTIFICATION MARKET SIZE, BY IMMUNOASSAY, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 109. GLOBAL BIOMANUFACTURING VIRAL DETECTION & QUANTIFICATION MARKET SIZE, BY IMMUNOASSAY, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 110. GLOBAL BIOMANUFACTURING VIRAL DETECTION & QUANTIFICATION MARKET SIZE, BY IMMUNOASSAY, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 111. GLOBAL BIOMANUFACTURING VIRAL DETECTION & QUANTIFICATION MARKET SIZE, BY CHEMILUMINESCENT IMMUNOASSAY, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 112. GLOBAL BIOMANUFACTURING VIRAL DETECTION & QUANTIFICATION MARKET SIZE, BY CHEMILUMINESCENT IMMUNOASSAY, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 113. GLOBAL BIOMANUFACTURING VIRAL DETECTION & QUANTIFICATION MARKET SIZE, BY CHEMILUMINESCENT IMMUNOASSAY, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 114. GLOBAL BIOMANUFACTURING VIRAL DETECTION & QUANTIFICATION MARKET SIZE, BY CHEMILUMINESCENT IMMUNOASSAY, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 115. GLOBAL BIOMANUFACTURING VIRAL DETECTION & QUANTIFICATION MARKET SIZE, BY CHEMILUMINESCENT IMMUNOASSAY, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 116. GLOBAL BIOMANUFACTURING VIRAL DETECTION & QUANTIFICATION MARKET SIZE, BY CHEMILUMINESCENT IMMUNOASSAY, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 117. GLOBAL BIOMANUFACTURING VIRAL DETECTION & QUANTIFICATION MARKET SIZE, BY ELISA, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 118. GLOBAL BIOMANUFACTURING VIRAL DETECTION & QUANTIFICATION MARKET SIZE, BY ELISA, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 119. GLOBAL BIOMANUFACTURING VIRAL DETECTION & QUANTIFICATION MARKET SIZE, BY ELISA, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 120. GLOBAL BIOMANUFACTURING VIRAL DETECTION & QUANTIFICATION MARKET SIZE, BY ELISA, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 121. GLOBAL BIOMANUFACTURING VIRAL DETECTION & QUANTIFICATION MARKET SIZE, BY ELISA, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 122. GLOBAL BIOMANUFACTURING VIRAL DETECTION & QUANTIFICATION MARKET SIZE, BY ELISA, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 123. GLOBAL BIOMANUFACTURING VIRAL DETECTION & QUANTIFICATION MARKET SIZE, BY LATERAL FLOW ASSAY, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 124. GLOBAL BIOMANUFACTURING VIRAL DETECTION & QUANTIFICATION MARKET SIZE, BY LATERAL FLOW ASSAY, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 125. GLOBAL BIOMANUFACTURING VIRAL DETECTION & QUANTIFICATION MARKET SIZE, BY LATERAL FLOW ASSAY, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 126. GLOBAL BIOMANUFACTURING VIRAL DETECTION & QUANTIFICATION MARKET SIZE, BY LATERAL FLOW ASSAY, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 127. GLOBAL BIOMANUFACTURING VIRAL DETECTION & QUANTIFICATION MARKET SIZE, BY LATERAL FLOW ASSAY, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 128. GLOBAL BIOMANUFACTURING VIRAL DETECTION & QUANTIFICATION MARKET SIZE, BY LATERAL FLOW ASSAY, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 129. GLOBAL BIOMANUFACTURING VIRAL DETECTION & QUANTIFICATION MARKET SIZE, BY NEXT GENERATION SEQUENCING, 2018-2024 (USD MILLION)
  • TABLE 130. GLOBAL BIOMANUFACTURING VIRAL DETECTION & QUANTIFICATION MARKET SIZE, BY NEXT GENERATION SEQUENCING, 2025-2032 (USD MILLION)
  • TABLE 131. GLOBAL BIOMANUFACTURING VIRAL DETECTION & QUANTIFICATION MARKET SIZE, BY NEXT GENERATION SEQUENCING, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 132. GLOBAL BIOMANUFACTURING VIRAL DETECTION & QUANTIFICATION MARKET SIZE, BY NEXT GENERATION SEQUENCING, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 133. GLOBAL BIOMANUFACTURING VIRAL DETECTION & QUANTIFICATION MARKET SIZE, BY NEXT GENERATION SEQUENCING, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 134. GLOBAL BIOMANUFACTURING VIRAL DETECTION & QUANTIFICATION MARKET SIZE, BY NEXT GENERATION SEQUENCING, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 135. GLOBAL BIOMANUFACTURING VIRAL DETECTION & QUANTIFICATION MARKET SIZE, BY NEXT GENERATION SEQUENCING, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 136. GLOBAL BIOMANUFACTURING VIRAL DETECTION & QUANTIFICATION MARKET SIZE, BY NEXT GENERATION SEQUENCING, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 137. GLOBAL BIOMANUFACTURING VIRAL DETECTION & QUANTIFICATION MARKET SIZE, BY ILLUMINA SEQUENCING, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 138. GLOBAL BIOMANUFACTURING VIRAL DETECTION & QUANTIFICATION MARKET SIZE, BY ILLUMINA SEQUENCING, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 139. GLOBAL BIOMANUFACTURING VIRAL DETECTION & QUANTIFICATION MARKET SIZE, BY ILLUMINA SEQUENCING, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 140. GLOBAL BIOMANUFACTURING VIRAL DETECTION & QUANTIFICATION MARKET SIZE, BY ILLUMINA SEQUENCING, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 141. GLOBAL BIOMANUFACTURING VIRAL DETECTION & QUANTIFICATION MARKET SIZE, BY ILLUMINA SEQUENCING, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 142. GLOBAL BIOMANUFACTURING VIRAL DETECTION & QUANTIFICATION MARKET SIZE, BY ILLUMINA SEQUENCING, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 143. GLOBAL BIOMANUFACTURING VIRAL DETECTION & QUANTIFICATION MARKET SIZE, BY ION TORRENT SEQUENCING, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 144. GLOBAL BIOMANUFACTURING VIRAL DETECTION & QUANTIFICATION MARKET SIZE, BY ION TORRENT SEQUENCING, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 145. GLOBAL BIOMANUFACTURING VIRAL DETECTION & QUANTIFICATION MARKET SIZE, BY ION TORRENT SEQUENCING, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 146. GLOBAL BIOMANUFACTURING VIRAL DETECTION & QUANTIFICATION MARKET SIZE, BY ION TORRENT SEQUENCING, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 147. GLOBAL BIOMANUFACTURING VIRAL DETECTION & QUANTIFICATION MARKET SIZE, BY ION TORRENT SEQUENCING, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 148. GLOBAL BIOMANUFACTURING VIRAL DETECTION & QUANTIFICATION MARKET SIZE, BY ION TORRENT SEQUENCING, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 149. GLOBAL BIOMANUFACTURING VIRAL DETECTION & QUANTIFICATION MARKET SIZE, BY NANOPORE SEQUENCING, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 150. GLOBAL BIOMANUFACTURING VIRAL DETECTION & QUANTIFICATION MARKET SIZE, BY NANOPORE SEQUENCING, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 151. GLOBAL BIOMANUFACTURING VIRAL DETECTION & QUANTIFICATION MARKET SIZE, BY NANOPORE SEQUENCING, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 152. GLOBAL BIOMANUFACTURING VIRAL DETECTION & QUANTIFICATION MARKET SIZE, BY NANOPORE SEQUENCING, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 153. GLOBAL BIOMANUFACTURING VIRAL DETECTION & QUANTIFICATION MARKET SIZE, BY NANOPORE SEQUENCING, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 154. GLOBAL BIOMANUFACTURING VIRAL DETECTION & QUANTIFICATION MARKET SIZE, BY NANOPORE SEQUENCING, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 155. GLOBAL BIOMANUFACTURING VIRAL DETECTION & QUANTIFICATION MARKET SIZE, BY POLYMERASE CHAIN REACTION, 2018-2024 (USD MILLION)
  • TABLE 156. GLOBAL BIOMANUFACTURING VIRAL DETECTION & QUANTIFICATION MARKET SIZE, BY POLYMERASE CHAIN REACTION, 2025-2032 (USD MILLION)
  • TABLE 157. GLOBAL BIOMANUFACTURING VIRAL DETECTION & QUANTIFICATION MARKET SIZE, BY POLYMERASE CHAIN REACTION, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 158. GLOBAL BIOMANUFACTURING VIRAL DETECTION & QUANTIFICATION MARKET SIZE, BY POLYMERASE CHAIN REACTION, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 159. GLOBAL BIOMANUFACTURING VIRAL DETECTION & QUANTIFICATION MARKET SIZE, BY POLYMERASE CHAIN REACTION, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 160. GLOBAL BIOMANUFACTURING VIRAL DETECTION & QUANTIFICATION MARKET SIZE, BY POLYMERASE CHAIN REACTION, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 161. GLOBAL BIOMANUFACTURING VIRAL DETECTION & QUANTIFICATION MARKET SIZE, BY POLYMERASE CHAIN REACTION, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 162. GLOBAL BIOMANUFACTURING VIRAL DETECTION & QUANTIFICATION MARKET SIZE, BY POLYMERASE CHAIN REACTION, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 163. GLOBAL BIOMANUFACTURING VIRAL DETECTION & QUANTIFICATION MARKET SIZE, BY CONVENTIONAL PCR, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 164. GLOBAL BIOMANUFACTURING VIRAL DETECTION & QUANTIFICATION MARKET SIZE, BY CONVENTIONAL PCR, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 165. GLOBAL BIOMANUFACTURING VIRAL DETECTION & QUANTIFICATION MARKET SIZE, BY CONVENTIONAL PCR, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 166. GLOBAL BIOMANUFACTURING VIRAL DETECTION & QUANTIFICATION MARKET SIZE, BY CONVENTIONAL PCR, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 167. GLOBAL BIOMANUFACTURING VIRAL DETECTION & QUANTIFICATION MARKET SIZE, BY CONVENTIONAL PCR, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 168. GLOBAL BIOMANUFACTURING VIRAL DETECTION & QUANTIFICATION MARKET SIZE, BY CONVENTIONAL PCR, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 169. GLOBAL BIOMANUFACTURING VIRAL DETECTION & QUANTIFICATION MARKET SIZE, BY DIGITAL PCR, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 170. GLOBAL BIOMANUFACTURING VIRAL DETECTION & QUANTIFICATION MARKET SIZE, BY DIGITAL PCR, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 171. GLOBAL BIOMANUFACTURING VIRAL DETECTION & QUANTIFICATION MARKET SIZE, BY DIGITAL PCR, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 172. GLOBAL BIOMANUFACTURING VIRAL DETECTION & QUANTIFICATION MARKET SIZE, BY DIGITAL PCR, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 173. GLOBAL BIOMANUFACTURING VIRAL DETECTION & QUANTIFICATION MARKET SIZE, BY DIGITAL PCR, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 174. GLOBAL BIOMANUFACTURING VIRAL DETECTION & QUANTIFICATION MARKET SIZE, BY DIGITAL PCR, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 175. GLOBAL BIOMANUFACTURING VIRAL DETECTION & QUANTIFICATION MARKET SIZE, BY REAL-TIME PCR, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 176. GLOBAL BIOMANUFACTURING VIRAL DETECTION & QUANTIFICATION MARKET SIZE, BY REAL-TIME PCR, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 177. GLOBAL BIOMANUFACTURING VIRAL DETECTION & QUANTIFICATION MARKET SIZE, BY REAL-TIME PCR, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 178. GLOBAL BIOMANUFACTURING VIRAL DETECTION & QUANTIFICATION MARKET SIZE, BY REAL-TIME PCR, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 179. GLOBAL BIOMANUFACTURING VIRAL DETECTION & QUANTIFICATION MARKET SIZE, BY REAL-TIME PCR, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 180. GLOBAL BIOMANUFACTURING VIRAL DETECTION & QUANTIFICATION MARKET SIZE, BY REAL-TIME PCR, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 181. GLOBAL BIOMANUFACTURING VIRAL DETECTION & QUANTIFICATION MARKET SIZE, BY APPLICATION, 2018-2024 (USD MILLION)
  • TABLE 182. GLOBAL BIOMANUFACTURING VIRAL DETECTION & QUANTIFICATION MARKET SIZE, BY APPLICATION, 2025-2032 (USD MILLION)
  • TABLE 183. GLOBAL BIOMANUFACTURING VIRAL DETECTION & QUANTIFICATION MARKET SIZE, BY GENE THERAPY QUALITY CONTROL, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 184. GLOBAL BIOMANUFACTURING VIRAL DETECTION & QUANTIFICATION MARKET SIZE, BY GENE THERAPY QUALITY CONTROL, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 185. GLOBAL BIOMANUFACTURING VIRAL DETECTION & QUANTIFICATION MARKET SIZE, BY GENE THERAPY QUALITY CONTROL, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 186. GLOBAL BIOMANUFACTURING VIRAL DETECTION & QUANTIFICATION MARKET SIZE, BY GENE THERAPY QUALITY CONTROL, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 187. GLOBAL BIOMANUFACTURING VIRAL DETECTION & QUANTIFICATION MARKET SIZE, BY GENE THERAPY QUALITY CONTROL, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 188. GLOBAL BIOMANUFACTURING VIRAL DETECTION & QUANTIFICATION MARKET SIZE, BY GENE THERAPY QUALITY CONTROL, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 189. GLOBAL BIOMANUFACTURING VIRAL DETECTION & QUANTIFICATION MARKET SIZE, BY RESEARCH APPLICATIONS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 190. GLOBAL BIOMANUFACTURING VIRAL DETECTION & QUANTIFICATION MARKET SIZE, BY RESEARCH APPLICATIONS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 191. GLOBAL BIOMANUFACTURING VIRAL DETECTION & QUANTIFICATION MARKET SIZE, BY RESEARCH APPLICATIONS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 192. GLOBAL BIOMANUFACTURING VIRAL DETECTION & QUANTIFICATION MARKET SIZE, BY RESEARCH APPLICATIONS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 193. GLOBAL BIOMANUFACTURING VIRAL DETECTION & QUANTIFICATION MARKET SIZE, BY RESEARCH APPLICATIONS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 194. GLOBAL BIOMANUFACTURING VIRAL DETECTION & QUANTIFICATION MARKET SIZE, BY RESEARCH APPLICATIONS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 195. GLOBAL BIOMANUFACTURING VIRAL DETECTION & QUANTIFICATION MARKET SIZE, BY VACCINE DEVELOPMENT, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 196. GLOBAL BIOMANUFACTURING VIRAL DETECTION & QUANTIFICATION MARKET SIZE, BY VACCINE DEVELOPMENT, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 197. GLOBAL BIOMANUFACTURING VIRAL DETECTION & QUANTIFICATION MARKET SIZE, BY VACCINE DEVELOPMENT, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 198. GLOBAL BIOMANUFACTURING VIRAL DETECTION & QUANTIFICATION MARKET SIZE, BY VACCINE DEVELOPMENT, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 199. GLOBAL BIOMANUFACTURING VIRAL DETECTION & QUANTIFICATION MARKET SIZE, BY VACCINE DEVELOPMENT, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 200. GLOBAL BIOMANUFACTURING VIRAL DETECTION & QUANTIFICATION MARKET SIZE, BY VACCINE DEVELOPMENT, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 201. GLOBAL BIOMANUFACTURING VIRAL DETECTION & QUANTIFICATION MARKET SIZE, BY VIRAL LOAD MONITORING, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 202. GLOBAL BIOMANUFACTURING VIRAL DETECTION & QUANTIFICATION MARKET SIZE, BY VIRAL LOAD MONITORING, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 203. GLOBAL BIOMANUFACTURING VIRAL DETECTION & QUANTIFICATION MARKET SIZE, BY VIRAL LOAD MONITORING, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 204. GLOBAL BIOMANUFACTURING VIRAL DETECTION & QUANTIFICATION MARKET SIZE, BY VIRAL LOAD MONITORING, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 205. GLOBAL BIOMANUFACTURING VIRAL DETECTION & QUANTIFICATION MARKET SIZE, BY VIRAL LOAD MONITORING, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 206. GLOBAL BIOMANUFACTURING VIRAL DETECTION & QUANTIFICATION MARKET SIZE, BY VIRAL LOAD MONITORING, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 207. GLOBAL BIOMANUFACTURING VIRAL DETECTION & QUANTIFICATION MARKET SIZE, BY VIRAL SAFETY TESTING, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 208. GLOBAL BIOMANUFACTURING VIRAL DETECTION & QUANTIFICATION MARKET SIZE, BY VIRAL SAFETY TESTING, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 209. GLOBAL BIOMANUFACTURING VIRAL DETECTION & QUANTIFICATION MARKET SIZE, BY VIRAL SAFETY TESTING, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 210. GLOBAL BIOMANUFACTURING VIRAL DETECTION & QUANTIFICATION MARKET SIZE, BY VIRAL SAFETY TESTING, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 211. GLOBAL BIOMANUFACTURING VIRAL DETECTION & QUANTIFICATION MARKET SIZE, BY VIRAL SAFETY TESTING, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 212. GLOBAL BIOMANUFACTURING VIRAL DETECTION & QUANTIFICATION MARKET SIZE, BY VIRAL SAFETY TESTING, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 213. GLOBAL BIOMANUFACTURING VIRAL DETECTION & QUANTIFICATION MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 214. GLOBAL BIOMANUFACTURING VIRAL DETECTION & QUANTIFICATION MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
  • TABLE 215. GLOBAL BIOMANUFACTURING VIRAL DETECTION & QUANTIFICATION MARKET SIZE, BY ACADEMIC & RESEARCH INSTITUTIONS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 216. GLOBAL BIOMANUFACTURING VIRAL DETECTION & QUANTIFICATION MARKET SIZE, BY ACADEMIC & RESEARCH INSTITUTIONS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 217. GLOBAL BIOMANUFACTURING VIRAL DETECTION & QUANTIFICATION MARKET SIZE, BY ACADEMIC & RESEARCH INSTITUTIONS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 218. GLOBAL BIOMANUFACTURING VIRAL DETECTION & QUANTIFICATION MARKET SIZE, BY ACADEMIC & RESEARCH INSTITUTIONS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 219. GLOBAL BIOMANUFACTURING VIRAL DETECTION & QUANTIFICATION MARKET SIZE, BY ACADEMIC & RESEARCH INSTITUTIONS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 220. GLOBAL BIOMANUFACTURING VIRAL DETECTION & QUANTIFICATION MARKET SIZE, BY ACADEMIC & RESEARCH INSTITUTIONS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 221. GLOBAL BIOMANUFACTURING VIRAL DETECTION & QUANTIFICATION MARKET SIZE, BY CONTRACT RESEARCH ORGANIZATIONS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 222. GLOBAL BIOMANUFACTURING VIRAL DETECTION & QUANTIFICATION MARKET SIZE, BY CONTRACT RESEARCH ORGANIZATIONS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 223. GLOBAL BIOMANUFACTURING VIRAL DETECTION & QUANTIFICATION MARKET SIZE, BY CONTRACT RESEARCH ORGANIZATIONS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 224. GLOBAL BIOMANUFACTURING VIRAL DETECTION & QUANTIFICATION MARKET SIZE, BY CONTRACT RESEARCH ORGANIZATIONS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 225. GLOBAL BIOMANUFACTURING VIRAL DETECTION & QUANTIFICATION MARKET SIZE, BY CONTRACT RESEARCH ORGANIZATIONS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 226. GLOBAL BIOMANUFACTURING VIRAL DETECTION & QUANTIFICATION MARKET SIZE, BY CONTRACT RESEARCH ORGANIZATIONS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 227. GLOBAL BIOMANUFACTURING VIRAL DETECTION & QUANTIFICATION MARKET SIZE, BY DIAGNOSTIC LABORATORIES, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 228. GLOBAL BIOMANUFACTURING VIRAL DETECTION & QUANTIFICATION MARKET SIZE, BY DIAGNOSTIC LABORATORIES, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 229. GLOBAL BIOMANUFACTURING VIRAL DETECTION & QUANTIFICATION MARKET SIZE, BY DIAGNOSTIC LABORATORIES, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 230. GLOBAL BIOMANUFACTURING VIRAL DETECTION & QUANTIFICATION MARKET SIZE, BY DIAGNOSTIC LABORATORIES, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 231. GLOBAL BIOMANUFACTURING VIRAL DETECTION & QUANTIFICATION MARKET SIZE, BY DIAGNOSTIC LABORATORIES, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 232. GLOBAL BIOMANUFACTURING VIRAL DETECTION & QUANTIFICATION MARKET SIZE, BY DIAGNOSTIC LABORATORIES, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 233. GLOBAL BIOMANUFACTURING VIRAL DETECTION & QUANTIFICATION MARKET SIZE, BY HOSPITALS & CLINICS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 234. GLOBAL BIOMANUFACTURING VIRAL DETECTION & QUANTIFICATION MARKET SIZE, BY HOSPITALS & CLINICS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 235. GLOBAL BIOMANUFACTURING VIRAL DETECTION & QUANTIFICATION MARKET SIZE, BY HOSPITALS & CLINICS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 236. GLOBAL BIOMANUFACTURING VIRAL DETECTION & QUANTIFICATION MARKET SIZE, BY HOSPITALS & CLINICS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 237. GLOBAL BIOMANUFACTURING VIRAL DETECTION & QUANTIFICATION MARKET SIZE, BY HOSPITALS & CLINICS, BY COUNTRY, 2018-2024 (